SOI

In case you missed our webinar this week, you can still view it here: https://bit.ly/3kXeaRP. It focused on multiple sclerosis, EHP-101, and the Phase 2 clinical trial we are initiating. Our two MS Clinical Advisors, Dr. Juan Antonio García Merino and Dr. Emmanuelle Waubant joined and offered important insights.

Multiple Sclerosis & EHP's Unique Promising Therapeutic Approach This is "Multiple Sclerosis & EHP's Unique Promising Therapeutic Approach" by Emerald Health Pharmaceuticals on Vimeo, the home for high quality…

We are grateful for our investors and their (your) support in our mission. For anyone still interested in investing in our company, we have announced the final closing date of our Reg A+ offering will be March 28. View press release: https://bit.ly/3bz7vKk; View offering circular: https://bit.ly/3vhvBkz

We hope you are able to attend our first 2021 webinar on Tuesday, March 16th at 10am PST / 1pm EST. It is focused on multiple sclerosis, EHP’s promising new potential treatment and the Phase 2 clinical trial we are initiating. Our two MS Clinical Advisors, Dr. Juan Antonio García Merino and Dr. Emmanuelle Waubant, globally recognized key opinion leaders in the research
and treatment of patients with MS, offer their insights! Register today. http://bit.ly/30f8ety

We are pleased to announce we have started activities for the initiation of our Phase 2 clinical study of EHP-101 in multiple sclerosis. Read today’s press release here: https://bit.ly/38h6xjV

March is Multiple Sclerosis Awareness Month, so we want to recognize the more than two million people living with MS around the world and re-emphasize our commitment to working toward finding a new potential treatment. Our first webinar of 2021 is on March 16th and is focused on MS and the treatment landscape, and you’re welcome to attend. You can register here. http://bit.ly/30f8ety

Multiple Sclerosis & EHP’s Unique Promising Therapeutic Approach With EHP’s MS Clinical Advisors: Juan Antonio García Merino, MD, PhD, & Emmanuelle Waubant, MD, PhD

“Today is Rare Disease Day and we recognize the impact rare diseases have on people around the world, including patients, loved ones, friends, caregivers and healthcare professionals. Because of this, I want to re-emphasize our team’s steadfast commitment at EHP to help improve the lives of people living with systemic sclerosis and Huntington’s disease by continuing to advance our clinical programs for both diseases and contribute to the ongoing research and discovery of improved treatment paradigms.” – Dr. Jim DeMesa, President and CEO

We’re pleased to share that our team recently published a scientific article in the peer-reviewed journal, Molecular and Cellular Neuroscience, highlighting data supporting the potential of our lead drug product candidate, EHP-102, to treat Parkinson’s disease. Read our announcement here: https://bit.ly/3a5K4Yl

Lisa Sanford is EHP’s Chief Financial Officer. If you’re one of our valued shareholders, you may recognize her name from various communications you receive from us. She starts off our last webinar of 2020 - Meet EHP’s Senior Leadership Team - with a discussion on what some of her finance team’s priorities are in 2021 and the importance of our shareholder community. Watch her conversation clip here:
Watch her conversation clip here: https://bit.ly/3aM7JMv
Watch the full webinar here:https://bit.ly/2W7z8l8

Hear Insights from EHP’s Chief Financial Officer, Lisa Sanford This is "Hear Insights from EHP’s Chief Financial Officer, Lisa Sanford" by Emerald Health Pharmaceuticals on Vimeo, the home for high quality videos…